1[1]Yoshimura M,Yasue H,Ogawa H.Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure[J].Can J Physiol Pharmacol,2001,79:730.
2[2]Ogawa Y,Tamura N,Chmho H,et al.Brain natriumie peptide appears to act locally as an antifibrolJe factor in the heart[J].Can J Physiol Pharmacol,2001,79(8):723.
3[3]Tokola H,Hautala N,Marttila M,et al.Mechancial load in duced alterations in B-type natriuretic peptide gene expression[J].Can J Physiol Pharmacol,2001,79 (8):646.
5[5]Selvais PL,Donckier J E.Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure:influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation[J].Eur J Clin Inves-t,1998,28(8):636.
6[6]Okawa H,Horimoto H.Preischemic infusion of alpha2human atrial natriuretic peptide elicits myoprotection through a nitric oxide dependent mechanism[J].J Cardiol,2002,39(6):299.
7[7]Lin KF,Chao J,Chao L.Atrial natriuretic peptide gene delivery attenuates hypertension,cardiac hypertrophy,and renal injury in salt sensitive rats[J].Hum Gene Ther,2002,8(10):1429.
8[8]M arrison A.M orrison LK,Krishnaswamy P.et al.B type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea[J].AnnEmergMed,2002,39(3):131.
9[9]M aisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of B-type natriuretic peptide in the emergency diagnosjs of heart failure[J].N Engl J Med,2002,347:161.
2[1]Strauer BE.Ventricular function and coronary hemodynamics in hypertensive heart disease[J].Am J Cardiol,1997,44:999-1001.
3[2]Sodoh T,Minamimo N,Kangawa K,et al.C-type natriuretic peptide(CNP):a new member of the natriuretic peptide family identified in porcine brain[J].Biochem Biophys Res Commun,1990,168:863.
4[3]Furuya M,Aisaka K,Miyazaki T,et al.C-typer natriuretic peptide inhibits intimal thickening after vascular injury[J].Biochem Biophy Res Commun,1993,193(1):248-253.
5Qian JY, Haruno A, Asada Y, et al. Local expression of Ctype natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arter
6Yasuda S, Kanna M, Sakuragi S, et al. Local delivery of single low-dose of C-type natriuretic peptide, an endogenous vascular modulator, inhibits neointimal hyperplasia in a balloon-injured rabbit iliac artery model[J]. J Cardiovasc Pharmacol, 2002,39(6)
7Poulsen H, Olofsson P, Stijernquist M. Effectsof head-down tilt on atrial natriuretic peptide and the rennin system in pregnancy[J]. Hypertension, 1995, 25(6):1161-1165.
8Kishimoto I, Saito Y, Li Y, et al. Cross-talk between the natriuretic peptide system and the angiotensin system[J]. Nippon Rinsho, 2002,60(10) :1923-1928.
9Chen HH, Burnett JC. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system[J]. J Cardiovasc Pharmacol, 1998, 32(3): 22-28.
10Amin J, Carretero OA, Ito S. Mechanisms of action of atrial natriuretic factor and C-type natriuretic peptide[J]. Hypertension, 1996,27(3 Pt 2):684-687.
4Nybo M, Nielsen L B, Nielsen SJ , et al. Discordant expression of pro-B- type and pro-C-type natriuretic pep tide in newborn infants of mothers with type 1 diabetes[J]. Regul Pept, 2007,141 (1-3) : 135-139.
5Igarashi M,Jimbu Y, Hirata A, et al. Characterization of p lasma brain natriuretic peptide level in patients with type 2 diabetes[J]. Endocr J, 2005,52 (3) : 353-362.
6Beer S, Golay S, Bardy D, et al. Increased p lasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular comp lications [J]. Diabetes Metab, 2005,31 (6) : 567-573.
7Wondergem J, Strootman E G, Frolich M, et al. Circulating atrial natriuretic pep tide plasma levels as a marker for cardiac damage after radiotherapy [ J ]. Radiother Oncol, 2001, 58 (3) :295-301.
8Yufu K, Takahashi N, Nakagawa M, et al. Brain natriuretic peptide and cardiac autonomic function in type 2 diabetic patients[J]. Diabetes Res Clin Pract,2006,72(1) :12-19.
9Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy [ J ]. Diabetes Care, 2001,24 (25) :5210.
10Bian K, Murad F. Nitric oxide (NO) - biogenration, regulation, and relevance to human disease. Front Biosci ,2003,8:264 -278.
